Choose Your Country or Region

CDK

Choose Selective CDK Inhibitors

CDK Signaling Pathway Map

Isoform-selective Inhibitors

CDK Products

All (108)
CDK Inhibitors (97)
CDK Antibodies (10)
CDK Modulators (1)
New CDK Products

Catalog No.	Product Name	Information	Product Use Citations
E0072^New	Indirubin-3′-oxime	Indirubin-3′-oxime (IDR3O, I3O) is an indirubin analogue that shows favorable inhibitory activity targeting GSK-3β and CDKs. Indirubin-3′-oxime also inhibits JNKs with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM for JNK1, JNK2, and JNK3, respectively. Indirubin-3′-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity.
S0273	CDK2-IN-73 (CDK2-IN-4)	CDK2-IN-73 (CDK2-IN-4, CDK2 inhibitor 73) is a potent and selective inhibitor of CDK2 with IC50 of 44 nM for CDK2/cyclin A.
S0354	Alsterpaullone	Alsterpaullone (Alp, 9-Nitropaullone, NSC 705701) is a potent inhibitor of CDK with IC50 of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also acts as a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 of both 4 nM for GSK-3α and GSK-3β. Alsterpaullone induces apoptosis by activation of caspase-9. Alsterpaullone has antitumor activity and possesses potential for the treatment of neurodegenerative and proliferative disorders.
S0500	Purvalanol B	Purvalanol B (NG-95) is a potent and selective inhibitor of cyclin-dependent kinase (CDK) with IC50 of 6 nM, 6 nM, 9 nM and 6 nM for cdc2-cyclin B, CDK2-cyclin A, CDK2-cyclin E and CDK5-p35, respectively.
S0771	BRD6989	BRD6989 is a selective inhibitor of CDK8 and CDK19. BRD6989 upregulates IL-10. BRD6989 is an analog of the natural product cortistatin A (dCA).	Infect Drug Resist, 2021, 14:3135-3143
S1058	BI-1347	BI-1347 is small molecule inhibitor of Cyclin-dependent kinase 8(CDK8) with IC50 of 1.1 nM.
S1116	Palbociclib (PD-0332991) HCl	Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.	Mol Cancer Ther, 2022, 21(1):48-57 Nat Med, 2021, 10.1038/s41591-020-01168-7 Cancer Cell, 2021, S1535-6108(21)00383-4
S1145	SNS-032 (BMS-387032)	SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. SNS-032 (BMS-387032) induces apoptosis. Phase 1.	Cancers (Basel), 2021, 13(15)3906 Cell Death Dis, 2021, 12(11):1048 Cells, 2021, 10(3)550
S1153	Roscovitine (CYC202)	Roscovitine (CYC202, Seliciclib, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.	Nucleic Acids Res, 2021, 49(13):7492-7506 EMBO J, 2021, e99692 Front Cell Dev Biol, 2021, 9:662868
S1230	Flavopiridol (L86-8275)	Flavopiridol (L86-8275, Alvocidib, NSC 649890, HMR-1275) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4, CDK6, and CDK9 with IC50 values in the 20-100 nM range. It is more selective for CDK1, 2, 4, 6, 9 versus CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol induces autophagy and ER stress. Flavopiridol blocks HIV-1 replication. Phase 1/2.	Nature, 2021, 10.1038/s41586-021-03445-y Genome Res, 2021, 31(6):981-994 J Cell Biol, 2021, 220(7)e202008146
S1249	JNJ-7706621	JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6 in cell-free assays. It also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.	Cancers (Basel), 2021, 13(6)1205 Gland Surg, 2020, 9(2):558-574 EMBO J, 2019, 38(19):e101704
S1487	PHA-793887	PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM. It is greater than 6-fold more selective for CDK2, 5, and 7 than CDK1, 4, and 9. PHA-793887 induces cell-cycle arrest and apoptosis. Phase 1.	Cell, 2020, 182(3):685-712.e19 Cell, 2020, 182(3):685-712.e19 Mol Cell Biol, 2020, 40(4)
S1524	AT7519	AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM. It is less potent to CDK3 and little active to CDK7. AT7519 also inhibits GSK3β with IC50 of 89 nM. AT7519 induces apoptosis. Phase 2.	J Am Chem Soc, 2021, 10.1021/jacs.1c05386 Sci Rep, 2021, 11(1):17029 Fundam Clin Pharmacol, 2021, 10.1111/fcp.12709
S1572	BS-181 HCl	BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.	Cancers (Basel), 2020, 12(12)E3845 Neuroendocrinology, 2020, 10.1159/000509865 Epigenetics Chromatin, 2019, 12(1):11
S1579	Palbociclib (PD0332991) Isethionate	Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.	Mol Cancer Ther, 2022, 21(1):48-57 Nature, 2021, 10.1038/s41586-021-03445-y Nat Med, 2021, 10.1038/s41591-020-01168-7
S1949	Menadione (NSC 4170)	Menadione (NSC 4170, Vitamin K3), a fat-soluble compound, is an inhibitor of Cdc25 phosphatase and mitochondrial DNA polymerase γ (pol γ), used as a nutritional supplement.	Mol Cell, 2021, S1097-2765(21)00269-0 DNA Repair (Amst), 2021, 105:103152 BMC Urol, 2021, 21(1):96
S2009	Indirubin-3'-monoxime	Indirubin-3'-monoxime (Indirubin-3'-oxime) is a selective CDK inhibitor with IC50 of 0.18 μM, 0.44 μM, 0.25 μM, 3.33 μM, 0.065 μM for CDK1-cyclinB, CDK2-cyclinA, CDK2-cyclinE, CDK4-cyclinD1, CDK5-p35,respectively. Indirubin-3'-monoxime is a direct and selective 5-lipoxygenase inhibitor with IC50 of 7.8-10 µM.
S2014	BMS-265246	BMS-265246 is a potent and selective CDK1/2 inhibitor with IC50 of 6 nM/9 nM in a cell-free assay. It is 25-fold more selective for CDK1/2 than CDK4.	Cancers (Basel), 2020, 12(6):E1637 Nature, 2019, 10.1038/s41586-019-1607-3 Nature, 2019, 574(7777):268-272
S2621	AZD5438	AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM in cell-free assays. It is less potent to CDK5/6 and also inhibits GSK3β. Phase 1.	Nat Commun, 2021, 12(1):3946 J Clin Invest, 2020, 10.1172/JCI122462 Nat Commun, 2020, 11(1):71
S2642	1-Naphthyl PP1(1-NA-PP1)	1-Naphthyl PP1(1-NA-PP 1) is a highly selective and potent pan-PKD inhibitor with IC50 of 154.6 nM,133.4 nM and 109.4 nM for PKD1, PKD2 and PKD3, respectively. 1-Naphthyl PP1 is a selective inhibitor of Src family kinases (v-Src, c-Fyn) and the tyrosine kinase c-Abl with IC50 of 1.0 μM, 0.6 μM, 0.6 μM, 18 μM and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II, respectively.
S2670	A-674563	A-674563 is an Akt1 inhibitor with K_i of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.	Sci Signal, 2020, 13(619) Cancers (Basel), 2020, 12(9)E2668 Biomolecules, 2020, 10(2)
S2672	PF-00562271 Besylate	PF-00562271 Besylate (PF-562271) is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.	Sci Adv, 2021, 7(40):eabh0363 J Nanobiotechnology, 2021, 19(1):175 Cells, 2021, 10(3)663
S2679	Flavopiridol (L86-8275) HCl	Flavopiridol HCl (L86-8275, NSC 649890, Alvocidib, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.	Nature, 2021, 10.1038/s41586-021-03445-y Genome Res, 2021, 31(6):981-994 EMBO Rep, 2021, e52023
S2688	R547	R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1/2/4 with K_i of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kinases. Phase 1.	Cell, 2020, 182(3):685-712.e19 Cell, 2020, 182(3):685-712.e19 Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486
S2735	MK-8776 (SCH 900776)	MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.	Nat Genet, 2021, 10.1038/s41588-021-00893-0 Mol Cell, 2021, 81(19):4041-4058.e15 Nat Commun, 2021, 12(1):6667
S2742	PHA-767491	PHA-767491 (CAY10572, NMS 1116354) is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM in cell-free assays, respectively.It displays ~20-fold selectivity against CDK1/2 and GSK3-β, 50-fold selectivity against MK2 and CDK5, 100-fold selectivity against PLK1 and CHK2.	Mol Cell, 2021, 81(3):426-441.e8 Mol Cell, 2021, S1097-2765(21)00649-3 Mol Cell, 2021, S1097-2765(21)00683-3
S2751	Milciclib (PHA-848125)	Milciclib (PHA-848125) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. Milciclib (PHA-848125) induces cell death through autophagy. Phase 2.	Sci Rep, 2021, 11(1):7259 Eur J Pharm Sci, 2021, 159:105740 Eur J Pharm Sci, 2021, S0928-0987(21)00042-7
S2768	Dinaciclib (SCH727965)	Dinaciclib (SCH727965, PS-095760) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.	Cell, 2021, 184(25):6119-6137.e26 Gut, 2021, 70(5):890-899 Sci Adv, 2021, 7(7)eabd2645
S2890	PF-562271	PF-562271 (PF-00562271) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.	Sci Adv, 2021, 7(40):eabh0363 Elife, 2021, 10e63093 J Nanobiotechnology, 2021, 19(1):175
S3224	Cinobufagin	Cinobufagin (Cinobufagine), an active ingredient of Venenum Bufonis, inhibits tumor development. Cinobufagin increases ATM and Chk2 and decreases CDC25C, CDK1, and cyclin B. Cinobufagin inhibits PI3K, AKT and Bcl-2 while increases levels of cleaved caspase-9 and caspase-3. Thus, Cinobufagin induces cell cycle arrest at the G2/M phase and apoptosis.
S3238	Resibufogenin	Resibufogenin (Bufogenin, Recibufogenin), a component of huachansu with anticancer effect, triggers necroptosis through upregulating receptor-interacting protein kinase 3 (RIP3) and phosphorylating mixed lineage kinase domain-like protein at Ser358. Resibufogenin exerts cytotoxic effect by inducing reactive oxygen species (ROS) accumulation. Resibufogenin induces apoptosis and caspase-3 and caspase-8 activity. Resibufogenin increases Bax/Bcl-2 expression, and suppresses cyclin D1, cyclin E, PI3K, p-AKT, p-GSK3β and β-catenin protein expression.
S4454^New	FIT-039	FIT-039 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), suppressing replication of a broad spectrum of DNA viruses through inhibition of mRNA transcription.
S4482^New	Palbociclib	Palbociclib (Ibrance, PD 0332991) is a highly specific inhibitor of cyclin-dependent kinase 4 (Cdk4) and Cdk6 with IC50 of 11 nM and 16 nM, respectively.	Mol Cancer Ther, 2022, 21(1):48-57 Cell, 2021, 184(25):6119-6137.e26 Genome Biol, 2021, 22(1):176
S4743	Wogonin	Wogonin (Vogonin), a natural and biologically-active flavonoid found in plants, is an inhibitor of CDK9 and does not inhibit CDK2, CDK4 and CDK6 at doses that inhibit CDK9 activity; Also inhibits N-acetyltransferase.	J Surg Res, 2021, 263:236-244 Exp Ther Med, 2015, 10(3):1066-1070
S5187^New	Ribociclib hydrochloride	Ribociclib (LEE011) hydrochloride is a highly specific dual inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM, respectively.	Biochim Biophys Acta Mol Cell Res, 2021, 1868(7):119044 Mol Cancer Res, 2021, 19(6):1026-1039 Front Oncol, 2021, 11:681530
S5188^New	Ribociclib succinate	Ribociclib (LEE011) succinate (Kisqali) is a highly specific dual inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM, respectively.	Biochim Biophys Acta Mol Cell Res, 2021, 1868(7):119044 Mol Cancer Res, 2021, 19(6):1026-1039 Front Oncol, 2021, 11:681530
S5316	NU2058	NU2058 (O(6)-Cyclohexylmethylguanine) is an inhibitor of CDK2 with IC50 value of 17 μM in an isolated enzyme assay. It also potentiates melphalan (DMF 2.3), and monohydroxymelphalan (1.7), but not temozolomide or ionising radiation.
S5716	Abemaciclib (LY2835219)	Abemaciclib (LY2835219) is a cell cycle inhibitor selective for CDK4/6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively.	Nat Med, 2021, 10.1038/s41591-020-01212-6 Nat Commun, 2021, 12(1):5386 Cancers (Basel), 2021, 13(19)5025
S5953^New	Menadione bisulfite sodium	Menadione(Vitamin K3) bisulfite sodium, a fat-soluble compound, is an inhibitor of Cdc25 phosphatase and mitochondrial DNA polymerase γ (pol γ), used as a nutritional supplement.	Life Sci, 2020, 242:117159
S6383^New	1-NM-PP1	1-NM-PP1 (PP1 Analog II, 1NM-PP1, analogue 9) is a potent inhibitor of Src family kinases with IC50 of 4.3 nM and 3.2 nM for v-Src-as1 and c-Fyn-as1, respectively. 1-NM-PP1 also inhibits CDK2-as1, CAMKII-as1 and c-Abl-as2 with IC50 of 5.0 nM, 8.0 nM and 120 nM, respectively.
S6531	Bohemine	Bohemine is a CDK inhibitor with IC50s of 4.6, 83, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively.
S6537	CVT-313	CVT-313 is a potent CDK2 inhibitor with an IC50 of 0.5 microM in vitro. It has no effect on other, nonrelated ATP-dependent serine/threonine kinases.	Nucleic Acids Res, 2021, gkab643
S6540	NG 52	NG-52 is a tri-substituted purine that binds to the ATP-binding site of yeast cyclin-dependent kinases, inhibiting Cdc28p and Pho85p with IC50s of 7 and 2 μM, respectively.
S6595	THZ531	THZ531 is a selective covalent inhibitor of CDK12 and CDK13 with IC50 values of 158 and 69 nM, respectively.	Neuroendocrinology, 2020, 10.1159/000509865
S6768^New	CC-671	CC-671 is a selectively dual inhibitor of TTK (human protein kinase monopolar spindle 1 [hMps1]) and CDC like kinase 2 (CLK2) with IC50s of 5 nM and 3 nM for TTK and CLK2, respectively.
S6777	NSC95397	NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor with Ki of 32 nM, 96 nM, 40 nM for Cdc25A, Cdc25B and Cdc25C, respectively. NSC 95397 has IC50 of 22.3 nM, 56.9 nM and 125 nM for human Cdc25A, human Cdc25C and Cdc25B, respectively. NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway.
S6871	Sodium oxamate	Sodium oxamate (SO, Aminooxoacetic acid, Oxamic acid) is an inhibitor of lactate dehydrogenase (LDH) that specificly inhibits LDH‑A. Sodium oxamate (SO) induces G2/M cell cycle arrest via downregulation of the CDK1/cyclin B1 pathway and promotes apoptosis through enhancement of mitochondrial ROS generation.	Aging (Albany NY), 2021, 13(24):25920-25930 Int J Biol Sci, 2021, 17(11):2756-2769
S6884^New	LY3405105	LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.
S6885	Ailanthone	Ailanthone (AIL, Δ13-Dehydrochaparrinone), a natural anti-hepatocellular carcinoma (HCC) component in Ailanthus altissima, induces G0/G1-phase cell cycle arrest by decreasing expression of cyclins and CDKs and increases expression of p21 and p27. Ailanthone triggers DNA damage characterized by activation of the ATM/ATR pathway. Ailanthone induces apoptosis which is mitochondrion-mediated and involves the PI3K/AKT signaling pathway in Huh7 cells. Ailanthone is also a potent inhibitor of both full-length Androgen Receptor (AR-FL) and constitutively active truncated AR splice variants (AR-Vs, AR_1-651) with IC50 of 69 nM and 309 nM, respectively.
S7114	NU6027	NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.	Nucleic Acids Res, 2021, gkab584
S7158	Abemaciclib mesylate (LY2835219)	Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.	Nat Med, 2021, 10.1038/s41591-020-01212-6 Cancer Cell, 2021, S1535-6108(20)30609-7 Nat Commun, 2021, 12(1):3356
S7198	BIO	BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.	Mol Cell, 2021, 81(18):3803-3819.e7 Cell Chem Biol, 2021, S2451-9456(21)00303-2 Front Cell Dev Biol, 2021, 9:662868
S7320	TG003	TG003 is a potent and ATP-competitive Cdc2-like kinase (Clk) inhibitor with IC50 of 20 nM, 200 nM, and 15 nM for Clk1, Clk2, and Clk4, respectively. No inhibitory effect on Clk3, SRPK1, SRPK2, or PKC.	Mol Cell, 2020, 80(6):1104-1122.e9 Nat Commun, 2020, 22;11(1):1931 Gastric Cancer, 2020, 24
S7357	PF-562271 HCl	PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.	Sci Adv, 2021, 7(40):eabh0363 Elife, 2021, 10e63093 J Nanobiotechnology, 2021, 19(1):175
S7371^New	Fadraciclib (CYC065)	Fadraciclib (CYC065) is a novel, orally available ATP-competitive inhibitor of CDK2/CDK9 kinases with IC50 of 5 nM and 26 nM, respectively.
S7440	Ribociclib (LEE011)	Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.	Cancer Cell, 2021, S1535-6108(21)00492-X Nat Commun, 2021, 12(1):3356 Cancers (Basel), 2021, 13(3)E372
S7461	LDC000067	LDC000067 (LDC067) is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.	Cell Rep, 2021, 35(11):109233 Autophagy, 2021, 1-19 Aging (Albany NY), 2021, 13(11):14892-14909
S7509	ML167	ML167 (CID 44968231) is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC50 of 136 nM, >10-fold selectivity for closely related kinases Clk1-3 and Dyrk1A/1B.	SLAS Discov, 2018, 23(8):850-861
S7511	LY2857785	LY2857785 is a type I reversible and competitive ATP kinase inhibitor against CDK9(IC50=0.011 μM) and also inhibits other transcription kinases CDK8(IC50=0.016 μM) and CDK7 (IC50=0.246 μM).	Cancers (Basel), 2021, 13(15)3906
S7547	XL413 (BMS-863233)	XL413 (BMS-863233) is a potent and selective cell division cycle 7 homolog (CDC7) kinase inhibitor with IC50 of 3.4 nM, showing 63-, 12- and 35-fold selectivity over CK2, Pim-1 and pMCM2, respectively. Phase 1/2.	Nucleic Acids Res, 2021, gkab628 Mol Syst Biol, 2021, 17(11):e10396 Cell, 2020, 182(3):685-712.e19
S7549	THZ1 2HCl	THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7.	Nature, 2021, 10.1038/s41586-021-04116-8 ACS Nano, 2021, 10.1021/acsnano.1c04570 Sci Adv, 2021, 7(48):eabf6123
S7636	SU9516	SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.	Cell Chem Biol, 2019, 26(1):121-130 Biotechnol Lett, 2017, 39(7):951-957
S7648	OTS964	OTS964 is a potent TOPK inhibitor with high affinity and selectivity and IC50 value is 28 nM. OTS964 is also a potent inhibitor of the cyclin-dependent kinase CDK11 with Kd of 40 nM. OTS964 treatment activates autophagy in glioma cells and induces apoptosis of human lung cancer cells in mouse xenografts.	Mol Imaging Biol, 2019, 21(4):705-712
S7747	Ro-3306	RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.	Science, 2021, 371(6535)eabc5386 Cancer Cell, 2021, S1535-6108(21)00659-0 Mol Cell, 2021, S1097-2765(20)30951-5
S7773	CDKI-73	CDKI-73 (LS-007) is a potent CDK inhibitor in vitro with IC50 of 8.17 nM, 3.27 nM, 8.18 nM, and 5.78 nM for CDK1, CDK2, CDK4, and CDK9, respectively. CDKI-73 induces apoptosis in cancer cells. CDKI-73 is an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
S7793	Purvalanol A	Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. Purvalanol A induces endoplasmic reticulum stress-mediated apoptosis and autophagy.	Cancer Lett, 2021, 526:53-65 Mol Neurobiol, 2021, 10.1007/s12035-021-02581-w Aging (Albany NY), 2020, 12(19):19022-19044
S7808	AT7519 HCl	AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.	Sci Rep, 2021, 11(1):17029 Fundam Clin Pharmacol, 2021, 10.1111/fcp.12709 Exp Mol Med, 2020, 10.1038/s12276-020-00537-z
S7917	Kenpaullone	Kenpaullone (9-Bromopaullone, NSC-664704) is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs). It also inhibit glycogen synthase kinase 3β (GSK3β) with IC50 of 0.23 µM.	Cell, 2020, 182(3):685-712.e19 Cell, 2020, 182(3):685-712.e19 Antiviral Res, 2019, 170:104572
S7969	THZ2	THZ2, a THZ1 analog, is a selective inhibitor of CDK7 with IC50 of 13.9 nM. THZ2 efficiently suppresses the clonogenic growth of TNBC cells with IC50 of ~10 nM.
S7992	LDC4297 (LDC044297)	LDC4297 is a novel CDK7 inhibitor (IC50=0.13±0.06 nM for CDK7 versus IC50s between 10 nM and 10,000 nM for all other analyzed CDKs).	Mol Cell, 2021, S1097-2765(20)30956-4 Mol Cell, 2019, 74(4):674-687
S8058	Riviciclib hydrochloride (P276-00)	Riviciclib hydrochloride (P276-00) is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. Riviciclib hydrochloride (P276-00) induces apoptosis. Phase 2/3.	Arthritis Res Ther, 2021, 23(1):47 BMC Genomics, 2021, 22(1):160 Mol Cell, 2020, 77(6):1322-1339
S8100	K03861	K03861 (AUZ 454，AUZ454) is a type II CDK2 inhibitor with K_d of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely.	Bone, 2021, 145:115837 Cancers (Basel), 2020, 12(6):E1637 Mol Oncol, 2020, 14(12):3153-3168
S8161	ON123300	ON123300 is a potent and multi-targeted kinase inhibitor with IC50 of 3.9 nM, 5 nM, 26 nM, 26 nM, 9.2 nM and 11nM for CDK4, Ark5/NUAK1, PDGFRβ, FGFR1, RET (c-RET), and Fyn, respectively.	J Cell Sci, 2021, jcs.258685 Molecules, 2020, 8;25(9) pii: E2220
S8387	MSC2530818	MSC2530818, a CDK8 inhibitor with the IC50 of 2.6 nM, displays excellent kinase selectivity, biochemical and cellular potency, microsomal stability, and is orally bioavailable.	Cell Stem Cell, 2021, 28(6):1105-1124.e19 Nat Biomed Eng, 2021, 10.1038/s41551-021-00757-2 STAR Protoc, 2021, 2(4):100913
S8389	Trilaciclib (G1T28)	Trilaciclib (G1T28, G1T28-1) is a highly potent, selective and reversible cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Trilaciclib inhibits CDK4/cyclin D1 and CDK6/cyclin D3 with IC50 of 1 nM and 4 nM, respectively.
S8520	Senexin A	Senexin A is a potent and selective inhibitor of CDK8 and its nearest relative, CDK19 with Kd values of 0.83 μM and 0.31 μM for CDK8 and CDK19 ATP site binding, respectively.
S8568	G1T38	G1T38 (Lerociclib) is a novel, potent, selective, and orally bioavailable CDK4/6 inhibitor with IC50 values of 0.001 μM, 0.002 μM and 0.028 μM for CDK4, CDK6 and CDK9 respectively.
S8719	AZD4573	AZD4573 is a potent inhibitor of CDK9 (IC50 of <0.004 μM) with fast-off binding kinetics (t_1/2 = 16 min) and high selectivity versus other kinases, including other CDK family kinases.	Cancers (Basel), 2021, 13(15)3906 Front Cell Dev Biol, 2021, 9:641271 Cell Chem Biol, 2020, S2451-9456(20)30380-9
S8722	Samuraciclib (ICEC0942)	Samuraciclib (ICEC0942, CT7001) is a new, orally bioavailable CDK7 inhibitor with an IC50 of 40nM. The IC50 values for CDK1, CDK2, CDK5 and CDK9 were 45-, 15-, 230- and 30-fold higher. ICEC0942 (CT7001) promotes cell cycle arrest and apoptosis.	Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-20-3458
S8727	Atuveciclib (BAY-1143572)	Atuveciclib (BAY-1143572) is potent and highly selective PTEFb/CDK9 inhibitor with IC50 values of 13 nM for CDK9/CycT and the ratio of IC50 values for CDK2/CDK9 is about 100. Outside the CDK family, It inhibits GSK3 kinase with IC50 values of 45 nM and 87 nM for GSK3α and GSK3β respectively.	Nat Commun, 2021, 12(1):7213 Bulletin of the Korean Chemical Society, 2021, 42(3):416-419 Cell Chem Biol, 2020, S2451-9456(20)30380-9
S8730	BAY 1251152	BAY1251152 is a potent PTEFb/CDK9 inhibitor with an IC50 value of 3 nM for CDK9 and an at least 50-fold selectivity against other CDKs in enzymatic assays. BAY1251152 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of gene transcription of various anti-apoptotic proteins.	Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-20-3458
S8783	JSH-150	JSH-150 is a highly selective and potent inhibitor of CDK9 with IC50 of 1 nM.
S8809	MC180295	MC180295 ((rel)-MC180295) is a novel potent and selective CDK9 inhibitor with an IC50 of 5 nM and is at least 22-fold more selective for CDK9 over other CDKs.
S8815	BSJ-03-123	BSJ-03-123 is a phthalimide-based degrader of cyclin-dependent kinase 6 (CDK6). (PROTAC)
S8840	SEL120 (SEL120-34A) hydrochloride	SEL120 (SEL120-34, SEL120-34A) is a novel inhibitor of Cyclin-dependent kinase 8 (CDK8) with IC50 values of 4.4 nM and 10.4 nM for CDK8/Cyclin C and CDK19/CyclinC respectively.
S8863	YKL-5-124	YKL-5-124 is a potent, selective and covalent CDK7 inhibitor with an IC50 of 9.7 nM, 1300 nM and 3020 nM for inhibiting CDK7/Mat1/CycH, CDK2 and CDK9 respectively. It displays biochemical and cellular selectivity for CDK7 over CDK12/13.	Cell, 2021, 184(25):6119-6137.e26 Cell Rep, 2021, 35(4):109013
S8894	SR-4835	SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13 with IC50 of 99 nM and Kd of 98 nM for CDK12 and IC50 of 4.9 nM for CDK13. SR-4835 disables triple-negative breast cancer (TNBC) cells. SR-4835 promotes synergy with DNA-damaging chemotherapy and PARP inhibitors.
S8903	AS2863619	AS2863619 is a small-molecule cyclin-dependent kinase CDK8/19 inhibitor with IC50 of 0.6099 nM and 4.277 nM, respectively. AS2863619 is a potent Foxp3 inducer in T_conv cells.
S8979	THAL-SNS-032	THAL-SNS-032 is a selective Cyclin-dependent kinase 9 (CDK9) degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN).
S8981	NVP-2	NVP-2, a potent, selective, non-neurotoxic and ATP-competitive cyclin dependent kinase 9 (CDK9) inhibitor with IC50 of 0.514 nM for CDK9/CycT activity and induces cell apoptosis.
S9605	Apcin	Apcin (APC inhibitor) is an inhibitor of the E3 ligase activity of the mitotic anaphase-promoting complex/cyclosome (APC/C) that binds to Cdc20 and competitively inhibits the ubiquitylation of D-box-containing substrates.	Prostate, 2021, 10.1002/pros.24257 Breast Cancer, 2021, 10.1007/s12282-021-01242-z
S9650^New	LY3143921 hydrate	LY3143921 hydrate is an orally administered ATP-competitive CDC7 inhibitor.
S9665	Motixafortide (BL-8040)	Motixafortide (BL-8040, BKT140, TF 14016, 4-fluorobenzoyl, 4F-benzoyl-TN14003, T140) is an antagonist of CXCR4 with IC50 of ～1 nM. BL-8040 induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
S9742^New	Indisulam	Indisulam (E7070), a sulfonamide anticancer agent, is a potent carbonic anhydrase (CA) inhibitor that inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Indisulam suppresses the expression of cyclin E and phosphorylation of CDK2, both of which are essential for the G1 to S transition.
S9859^New	BSJ-4-116	BSJ-4-116 is a specific degrader of cyclin-dependent kinase 12 (CDK12). BSJ-4-116 exhibits potent antiproliferative effects.
S9880^New	MS140	MS140 is a specific and highly potent CDK4/6 kinase inhibitor and also a CDK4/6 degrader (PROTAC).
S9901^New	KB-0742 Dihydrochloride	KB-0742 Dihydrochloride is a potent, selective, and orally bioavailable small molecule inhibitor of the transcription elongation cofactor CDK9 with IC50 of 6 nM for CDK9/cyclin T1 inhibition at 10 μM ATP.
A5016	Cyclin B1 Rabbit Recombinant mAb	Cyclin B1 Rabbit Recombinant mAb detects endogenous levels of total Cyclin B1.	Arch Biochem Biophys, 2021, 700:108774 Gastric Cancer, 2019, 10.1007/s10120-019-00977-1 Gastric Cancer, 2019, 10.1007/s10120-019-00977-1
A5053	p27 KIP1 Rabbit Recombinant mAb	p27 KIP1 Rabbit Recombinant mAb detects endogenous levels of total p27 KIP 1.	Aging (Albany NY), 2020, 12(16):16390-16409
A5081	Cdk8 Rabbit Recombinant mAb	Cdk8 Rabbit Recombinant mAb detects endogenous levels of CDK8.
A5127	Cyclin B2 Rabbit Recombinant mAb	Cyclin B2 Rabbit Recombinant mAb detects endogenous level of total Cyclin B2.
A5128	Cdk9 Rabbit Recombinant mAb	Cdk9 Rabbit Recombinant mAb detects endogenous level of total Cdk9.
A5129	Cdk6 Rabbit Recombinant mAb	Cdk6 Rabbit Recombinant mAb detects endogenous level of total Cdk6.
A5197	Cdc16/APC6 Rabbit Recombinant mAb	Cdc16/APC6 Rabbit Recombinant mAb detects endogenous level of total Cdc16/APC6.
A5198	CDC34 Rabbit Recombinant mAb	CDC34 Rabbit Recombinant mAb detects endogenous level of total CDC34.
A5200	Cdc37 Rabbit Recombinant mAb	Cdc37 Rabbit Recombinant mAb detects endogenous level of total Cdc37.
A5268	p57 Kip2 Rabbit Recombinant mAb	p57 Kip2 Rabbit Recombinant mAb detects endogenous level of total p57 Kip2.
S7981	CCT251545	CCT251545 is a potent, orally bioavailable inhibitor of WNT signaling with IC50 of 5 nM in 7dF3 cells. CCT251545 also act as a selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.	Front Cell Dev Biol, 2020, 8:408
E0072^New	Indirubin-3′-oxime	Indirubin-3′-oxime (IDR3O, I3O) is an indirubin analogue that shows favorable inhibitory activity targeting GSK-3β and CDKs. Indirubin-3′-oxime also inhibits JNKs with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM for JNK1, JNK2, and JNK3, respectively. Indirubin-3′-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity.
S0273	CDK2-IN-73 (CDK2-IN-4)	CDK2-IN-73 (CDK2-IN-4, CDK2 inhibitor 73) is a potent and selective inhibitor of CDK2 with IC50 of 44 nM for CDK2/cyclin A.
S0354	Alsterpaullone	Alsterpaullone (Alp, 9-Nitropaullone, NSC 705701) is a potent inhibitor of CDK with IC50 of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also acts as a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 of both 4 nM for GSK-3α and GSK-3β. Alsterpaullone induces apoptosis by activation of caspase-9. Alsterpaullone has antitumor activity and possesses potential for the treatment of neurodegenerative and proliferative disorders.
S0500	Purvalanol B	Purvalanol B (NG-95) is a potent and selective inhibitor of cyclin-dependent kinase (CDK) with IC50 of 6 nM, 6 nM, 9 nM and 6 nM for cdc2-cyclin B, CDK2-cyclin A, CDK2-cyclin E and CDK5-p35, respectively.
S0771	BRD6989	BRD6989 is a selective inhibitor of CDK8 and CDK19. BRD6989 upregulates IL-10. BRD6989 is an analog of the natural product cortistatin A (dCA).	Infect Drug Resist, 2021, 14:3135-3143
S1058	BI-1347	BI-1347 is small molecule inhibitor of Cyclin-dependent kinase 8(CDK8) with IC50 of 1.1 nM.
S1116	Palbociclib (PD-0332991) HCl	Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.	Mol Cancer Ther, 2022, 21(1):48-57 Nat Med, 2021, 10.1038/s41591-020-01168-7 Cancer Cell, 2021, S1535-6108(21)00383-4
S1145	SNS-032 (BMS-387032)	SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. SNS-032 (BMS-387032) induces apoptosis. Phase 1.	Cancers (Basel), 2021, 13(15)3906 Cell Death Dis, 2021, 12(11):1048 Cells, 2021, 10(3)550
S1153	Roscovitine (CYC202)	Roscovitine (CYC202, Seliciclib, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.	Nucleic Acids Res, 2021, 49(13):7492-7506 EMBO J, 2021, e99692 Front Cell Dev Biol, 2021, 9:662868
S1230	Flavopiridol (L86-8275)	Flavopiridol (L86-8275, Alvocidib, NSC 649890, HMR-1275) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4, CDK6, and CDK9 with IC50 values in the 20-100 nM range. It is more selective for CDK1, 2, 4, 6, 9 versus CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol induces autophagy and ER stress. Flavopiridol blocks HIV-1 replication. Phase 1/2.	Nature, 2021, 10.1038/s41586-021-03445-y Genome Res, 2021, 31(6):981-994 J Cell Biol, 2021, 220(7)e202008146
S1249	JNJ-7706621	JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6 in cell-free assays. It also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.	Cancers (Basel), 2021, 13(6)1205 Gland Surg, 2020, 9(2):558-574 EMBO J, 2019, 38(19):e101704
S1487	PHA-793887	PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM. It is greater than 6-fold more selective for CDK2, 5, and 7 than CDK1, 4, and 9. PHA-793887 induces cell-cycle arrest and apoptosis. Phase 1.	Cell, 2020, 182(3):685-712.e19 Cell, 2020, 182(3):685-712.e19 Mol Cell Biol, 2020, 40(4)
S1524	AT7519	AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM. It is less potent to CDK3 and little active to CDK7. AT7519 also inhibits GSK3β with IC50 of 89 nM. AT7519 induces apoptosis. Phase 2.	J Am Chem Soc, 2021, 10.1021/jacs.1c05386 Sci Rep, 2021, 11(1):17029 Fundam Clin Pharmacol, 2021, 10.1111/fcp.12709
S1572	BS-181 HCl	BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.	Cancers (Basel), 2020, 12(12)E3845 Neuroendocrinology, 2020, 10.1159/000509865 Epigenetics Chromatin, 2019, 12(1):11
S1579	Palbociclib (PD0332991) Isethionate	Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.	Mol Cancer Ther, 2022, 21(1):48-57 Nature, 2021, 10.1038/s41586-021-03445-y Nat Med, 2021, 10.1038/s41591-020-01168-7
S1949	Menadione (NSC 4170)	Menadione (NSC 4170, Vitamin K3), a fat-soluble compound, is an inhibitor of Cdc25 phosphatase and mitochondrial DNA polymerase γ (pol γ), used as a nutritional supplement.	Mol Cell, 2021, S1097-2765(21)00269-0 DNA Repair (Amst), 2021, 105:103152 BMC Urol, 2021, 21(1):96
S2009	Indirubin-3'-monoxime	Indirubin-3'-monoxime (Indirubin-3'-oxime) is a selective CDK inhibitor with IC50 of 0.18 μM, 0.44 μM, 0.25 μM, 3.33 μM, 0.065 μM for CDK1-cyclinB, CDK2-cyclinA, CDK2-cyclinE, CDK4-cyclinD1, CDK5-p35,respectively. Indirubin-3'-monoxime is a direct and selective 5-lipoxygenase inhibitor with IC50 of 7.8-10 µM.
S2014	BMS-265246	BMS-265246 is a potent and selective CDK1/2 inhibitor with IC50 of 6 nM/9 nM in a cell-free assay. It is 25-fold more selective for CDK1/2 than CDK4.	Cancers (Basel), 2020, 12(6):E1637 Nature, 2019, 10.1038/s41586-019-1607-3 Nature, 2019, 574(7777):268-272
S2621	AZD5438	AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM in cell-free assays. It is less potent to CDK5/6 and also inhibits GSK3β. Phase 1.	Nat Commun, 2021, 12(1):3946 J Clin Invest, 2020, 10.1172/JCI122462 Nat Commun, 2020, 11(1):71
S2642	1-Naphthyl PP1(1-NA-PP1)	1-Naphthyl PP1(1-NA-PP 1) is a highly selective and potent pan-PKD inhibitor with IC50 of 154.6 nM,133.4 nM and 109.4 nM for PKD1, PKD2 and PKD3, respectively. 1-Naphthyl PP1 is a selective inhibitor of Src family kinases (v-Src, c-Fyn) and the tyrosine kinase c-Abl with IC50 of 1.0 μM, 0.6 μM, 0.6 μM, 18 μM and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II, respectively.
S2670	A-674563	A-674563 is an Akt1 inhibitor with K_i of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.	Sci Signal, 2020, 13(619) Cancers (Basel), 2020, 12(9)E2668 Biomolecules, 2020, 10(2)
S2672	PF-00562271 Besylate	PF-00562271 Besylate (PF-562271) is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.	Sci Adv, 2021, 7(40):eabh0363 J Nanobiotechnology, 2021, 19(1):175 Cells, 2021, 10(3)663
S2679	Flavopiridol (L86-8275) HCl	Flavopiridol HCl (L86-8275, NSC 649890, Alvocidib, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.	Nature, 2021, 10.1038/s41586-021-03445-y Genome Res, 2021, 31(6):981-994 EMBO Rep, 2021, e52023
S2688	R547	R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1/2/4 with K_i of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kinases. Phase 1.	Cell, 2020, 182(3):685-712.e19 Cell, 2020, 182(3):685-712.e19 Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486
S2735	MK-8776 (SCH 900776)	MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.	Nat Genet, 2021, 10.1038/s41588-021-00893-0 Mol Cell, 2021, 81(19):4041-4058.e15 Nat Commun, 2021, 12(1):6667
S2742	PHA-767491	PHA-767491 (CAY10572, NMS 1116354) is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM in cell-free assays, respectively.It displays ~20-fold selectivity against CDK1/2 and GSK3-β, 50-fold selectivity against MK2 and CDK5, 100-fold selectivity against PLK1 and CHK2.	Mol Cell, 2021, 81(3):426-441.e8 Mol Cell, 2021, S1097-2765(21)00649-3 Mol Cell, 2021, S1097-2765(21)00683-3
S2751	Milciclib (PHA-848125)	Milciclib (PHA-848125) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. Milciclib (PHA-848125) induces cell death through autophagy. Phase 2.	Sci Rep, 2021, 11(1):7259 Eur J Pharm Sci, 2021, 159:105740 Eur J Pharm Sci, 2021, S0928-0987(21)00042-7
S2768	Dinaciclib (SCH727965)	Dinaciclib (SCH727965, PS-095760) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.	Cell, 2021, 184(25):6119-6137.e26 Gut, 2021, 70(5):890-899 Sci Adv, 2021, 7(7)eabd2645
S2890	PF-562271	PF-562271 (PF-00562271) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.	Sci Adv, 2021, 7(40):eabh0363 Elife, 2021, 10e63093 J Nanobiotechnology, 2021, 19(1):175
S3224	Cinobufagin	Cinobufagin (Cinobufagine), an active ingredient of Venenum Bufonis, inhibits tumor development. Cinobufagin increases ATM and Chk2 and decreases CDC25C, CDK1, and cyclin B. Cinobufagin inhibits PI3K, AKT and Bcl-2 while increases levels of cleaved caspase-9 and caspase-3. Thus, Cinobufagin induces cell cycle arrest at the G2/M phase and apoptosis.
S3238	Resibufogenin	Resibufogenin (Bufogenin, Recibufogenin), a component of huachansu with anticancer effect, triggers necroptosis through upregulating receptor-interacting protein kinase 3 (RIP3) and phosphorylating mixed lineage kinase domain-like protein at Ser358. Resibufogenin exerts cytotoxic effect by inducing reactive oxygen species (ROS) accumulation. Resibufogenin induces apoptosis and caspase-3 and caspase-8 activity. Resibufogenin increases Bax/Bcl-2 expression, and suppresses cyclin D1, cyclin E, PI3K, p-AKT, p-GSK3β and β-catenin protein expression.
S4454^New	FIT-039	FIT-039 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), suppressing replication of a broad spectrum of DNA viruses through inhibition of mRNA transcription.
S4482^New	Palbociclib	Palbociclib (Ibrance, PD 0332991) is a highly specific inhibitor of cyclin-dependent kinase 4 (Cdk4) and Cdk6 with IC50 of 11 nM and 16 nM, respectively.	Mol Cancer Ther, 2022, 21(1):48-57 Cell, 2021, 184(25):6119-6137.e26 Genome Biol, 2021, 22(1):176
S4743	Wogonin	Wogonin (Vogonin), a natural and biologically-active flavonoid found in plants, is an inhibitor of CDK9 and does not inhibit CDK2, CDK4 and CDK6 at doses that inhibit CDK9 activity; Also inhibits N-acetyltransferase.	J Surg Res, 2021, 263:236-244 Exp Ther Med, 2015, 10(3):1066-1070
S5187^New	Ribociclib hydrochloride	Ribociclib (LEE011) hydrochloride is a highly specific dual inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM, respectively.	Biochim Biophys Acta Mol Cell Res, 2021, 1868(7):119044 Mol Cancer Res, 2021, 19(6):1026-1039 Front Oncol, 2021, 11:681530
S5188^New	Ribociclib succinate	Ribociclib (LEE011) succinate (Kisqali) is a highly specific dual inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM, respectively.	Biochim Biophys Acta Mol Cell Res, 2021, 1868(7):119044 Mol Cancer Res, 2021, 19(6):1026-1039 Front Oncol, 2021, 11:681530
S5316	NU2058	NU2058 (O(6)-Cyclohexylmethylguanine) is an inhibitor of CDK2 with IC50 value of 17 μM in an isolated enzyme assay. It also potentiates melphalan (DMF 2.3), and monohydroxymelphalan (1.7), but not temozolomide or ionising radiation.
S5716	Abemaciclib (LY2835219)	Abemaciclib (LY2835219) is a cell cycle inhibitor selective for CDK4/6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively.	Nat Med, 2021, 10.1038/s41591-020-01212-6 Nat Commun, 2021, 12(1):5386 Cancers (Basel), 2021, 13(19)5025
S5953^New	Menadione bisulfite sodium	Menadione(Vitamin K3) bisulfite sodium, a fat-soluble compound, is an inhibitor of Cdc25 phosphatase and mitochondrial DNA polymerase γ (pol γ), used as a nutritional supplement.	Life Sci, 2020, 242:117159
S6383^New	1-NM-PP1	1-NM-PP1 (PP1 Analog II, 1NM-PP1, analogue 9) is a potent inhibitor of Src family kinases with IC50 of 4.3 nM and 3.2 nM for v-Src-as1 and c-Fyn-as1, respectively. 1-NM-PP1 also inhibits CDK2-as1, CAMKII-as1 and c-Abl-as2 with IC50 of 5.0 nM, 8.0 nM and 120 nM, respectively.
S6531	Bohemine	Bohemine is a CDK inhibitor with IC50s of 4.6, 83, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively.
S6537	CVT-313	CVT-313 is a potent CDK2 inhibitor with an IC50 of 0.5 microM in vitro. It has no effect on other, nonrelated ATP-dependent serine/threonine kinases.	Nucleic Acids Res, 2021, gkab643
S6540	NG 52	NG-52 is a tri-substituted purine that binds to the ATP-binding site of yeast cyclin-dependent kinases, inhibiting Cdc28p and Pho85p with IC50s of 7 and 2 μM, respectively.
S6595	THZ531	THZ531 is a selective covalent inhibitor of CDK12 and CDK13 with IC50 values of 158 and 69 nM, respectively.	Neuroendocrinology, 2020, 10.1159/000509865
S6768^New	CC-671	CC-671 is a selectively dual inhibitor of TTK (human protein kinase monopolar spindle 1 [hMps1]) and CDC like kinase 2 (CLK2) with IC50s of 5 nM and 3 nM for TTK and CLK2, respectively.
S6777	NSC95397	NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor with Ki of 32 nM, 96 nM, 40 nM for Cdc25A, Cdc25B and Cdc25C, respectively. NSC 95397 has IC50 of 22.3 nM, 56.9 nM and 125 nM for human Cdc25A, human Cdc25C and Cdc25B, respectively. NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway.
S6871	Sodium oxamate	Sodium oxamate (SO, Aminooxoacetic acid, Oxamic acid) is an inhibitor of lactate dehydrogenase (LDH) that specificly inhibits LDH‑A. Sodium oxamate (SO) induces G2/M cell cycle arrest via downregulation of the CDK1/cyclin B1 pathway and promotes apoptosis through enhancement of mitochondrial ROS generation.	Aging (Albany NY), 2021, 13(24):25920-25930 Int J Biol Sci, 2021, 17(11):2756-2769
S6884^New	LY3405105	LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.
S6885	Ailanthone	Ailanthone (AIL, Δ13-Dehydrochaparrinone), a natural anti-hepatocellular carcinoma (HCC) component in Ailanthus altissima, induces G0/G1-phase cell cycle arrest by decreasing expression of cyclins and CDKs and increases expression of p21 and p27. Ailanthone triggers DNA damage characterized by activation of the ATM/ATR pathway. Ailanthone induces apoptosis which is mitochondrion-mediated and involves the PI3K/AKT signaling pathway in Huh7 cells. Ailanthone is also a potent inhibitor of both full-length Androgen Receptor (AR-FL) and constitutively active truncated AR splice variants (AR-Vs, AR_1-651) with IC50 of 69 nM and 309 nM, respectively.
S7114	NU6027	NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.	Nucleic Acids Res, 2021, gkab584
S7158	Abemaciclib mesylate (LY2835219)	Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.	Nat Med, 2021, 10.1038/s41591-020-01212-6 Cancer Cell, 2021, S1535-6108(20)30609-7 Nat Commun, 2021, 12(1):3356
S7198	BIO	BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.	Mol Cell, 2021, 81(18):3803-3819.e7 Cell Chem Biol, 2021, S2451-9456(21)00303-2 Front Cell Dev Biol, 2021, 9:662868
S7320	TG003	TG003 is a potent and ATP-competitive Cdc2-like kinase (Clk) inhibitor with IC50 of 20 nM, 200 nM, and 15 nM for Clk1, Clk2, and Clk4, respectively. No inhibitory effect on Clk3, SRPK1, SRPK2, or PKC.	Mol Cell, 2020, 80(6):1104-1122.e9 Nat Commun, 2020, 22;11(1):1931 Gastric Cancer, 2020, 24
S7357	PF-562271 HCl	PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.	Sci Adv, 2021, 7(40):eabh0363 Elife, 2021, 10e63093 J Nanobiotechnology, 2021, 19(1):175
S7371^New	Fadraciclib (CYC065)	Fadraciclib (CYC065) is a novel, orally available ATP-competitive inhibitor of CDK2/CDK9 kinases with IC50 of 5 nM and 26 nM, respectively.
S7440	Ribociclib (LEE011)	Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.	Cancer Cell, 2021, S1535-6108(21)00492-X Nat Commun, 2021, 12(1):3356 Cancers (Basel), 2021, 13(3)E372
S7461	LDC000067	LDC000067 (LDC067) is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.	Cell Rep, 2021, 35(11):109233 Autophagy, 2021, 1-19 Aging (Albany NY), 2021, 13(11):14892-14909
S7509	ML167	ML167 (CID 44968231) is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC50 of 136 nM, >10-fold selectivity for closely related kinases Clk1-3 and Dyrk1A/1B.	SLAS Discov, 2018, 23(8):850-861
S7511	LY2857785	LY2857785 is a type I reversible and competitive ATP kinase inhibitor against CDK9(IC50=0.011 μM) and also inhibits other transcription kinases CDK8(IC50=0.016 μM) and CDK7 (IC50=0.246 μM).	Cancers (Basel), 2021, 13(15)3906
S7547	XL413 (BMS-863233)	XL413 (BMS-863233) is a potent and selective cell division cycle 7 homolog (CDC7) kinase inhibitor with IC50 of 3.4 nM, showing 63-, 12- and 35-fold selectivity over CK2, Pim-1 and pMCM2, respectively. Phase 1/2.	Nucleic Acids Res, 2021, gkab628 Mol Syst Biol, 2021, 17(11):e10396 Cell, 2020, 182(3):685-712.e19
S7549	THZ1 2HCl	THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7.	Nature, 2021, 10.1038/s41586-021-04116-8 ACS Nano, 2021, 10.1021/acsnano.1c04570 Sci Adv, 2021, 7(48):eabf6123
S7636	SU9516	SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.	Cell Chem Biol, 2019, 26(1):121-130 Biotechnol Lett, 2017, 39(7):951-957
S7648	OTS964	OTS964 is a potent TOPK inhibitor with high affinity and selectivity and IC50 value is 28 nM. OTS964 is also a potent inhibitor of the cyclin-dependent kinase CDK11 with Kd of 40 nM. OTS964 treatment activates autophagy in glioma cells and induces apoptosis of human lung cancer cells in mouse xenografts.	Mol Imaging Biol, 2019, 21(4):705-712
S7747	Ro-3306	RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.	Science, 2021, 371(6535)eabc5386 Cancer Cell, 2021, S1535-6108(21)00659-0 Mol Cell, 2021, S1097-2765(20)30951-5
S7773	CDKI-73	CDKI-73 (LS-007) is a potent CDK inhibitor in vitro with IC50 of 8.17 nM, 3.27 nM, 8.18 nM, and 5.78 nM for CDK1, CDK2, CDK4, and CDK9, respectively. CDKI-73 induces apoptosis in cancer cells. CDKI-73 is an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
S7793	Purvalanol A	Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. Purvalanol A induces endoplasmic reticulum stress-mediated apoptosis and autophagy.	Cancer Lett, 2021, 526:53-65 Mol Neurobiol, 2021, 10.1007/s12035-021-02581-w Aging (Albany NY), 2020, 12(19):19022-19044
S7808	AT7519 HCl	AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.	Sci Rep, 2021, 11(1):17029 Fundam Clin Pharmacol, 2021, 10.1111/fcp.12709 Exp Mol Med, 2020, 10.1038/s12276-020-00537-z
S7917	Kenpaullone	Kenpaullone (9-Bromopaullone, NSC-664704) is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs). It also inhibit glycogen synthase kinase 3β (GSK3β) with IC50 of 0.23 µM.	Cell, 2020, 182(3):685-712.e19 Cell, 2020, 182(3):685-712.e19 Antiviral Res, 2019, 170:104572
S7969	THZ2	THZ2, a THZ1 analog, is a selective inhibitor of CDK7 with IC50 of 13.9 nM. THZ2 efficiently suppresses the clonogenic growth of TNBC cells with IC50 of ~10 nM.
S7992	LDC4297 (LDC044297)	LDC4297 is a novel CDK7 inhibitor (IC50=0.13±0.06 nM for CDK7 versus IC50s between 10 nM and 10,000 nM for all other analyzed CDKs).	Mol Cell, 2021, S1097-2765(20)30956-4 Mol Cell, 2019, 74(4):674-687
S8058	Riviciclib hydrochloride (P276-00)	Riviciclib hydrochloride (P276-00) is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. Riviciclib hydrochloride (P276-00) induces apoptosis. Phase 2/3.	Arthritis Res Ther, 2021, 23(1):47 BMC Genomics, 2021, 22(1):160 Mol Cell, 2020, 77(6):1322-1339
S8100	K03861	K03861 (AUZ 454，AUZ454) is a type II CDK2 inhibitor with K_d of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely.	Bone, 2021, 145:115837 Cancers (Basel), 2020, 12(6):E1637 Mol Oncol, 2020, 14(12):3153-3168
S8161	ON123300	ON123300 is a potent and multi-targeted kinase inhibitor with IC50 of 3.9 nM, 5 nM, 26 nM, 26 nM, 9.2 nM and 11nM for CDK4, Ark5/NUAK1, PDGFRβ, FGFR1, RET (c-RET), and Fyn, respectively.	J Cell Sci, 2021, jcs.258685 Molecules, 2020, 8;25(9) pii: E2220
S8387	MSC2530818	MSC2530818, a CDK8 inhibitor with the IC50 of 2.6 nM, displays excellent kinase selectivity, biochemical and cellular potency, microsomal stability, and is orally bioavailable.	Cell Stem Cell, 2021, 28(6):1105-1124.e19 Nat Biomed Eng, 2021, 10.1038/s41551-021-00757-2 STAR Protoc, 2021, 2(4):100913
S8389	Trilaciclib (G1T28)	Trilaciclib (G1T28, G1T28-1) is a highly potent, selective and reversible cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Trilaciclib inhibits CDK4/cyclin D1 and CDK6/cyclin D3 with IC50 of 1 nM and 4 nM, respectively.
S8520	Senexin A	Senexin A is a potent and selective inhibitor of CDK8 and its nearest relative, CDK19 with Kd values of 0.83 μM and 0.31 μM for CDK8 and CDK19 ATP site binding, respectively.
S8568	G1T38	G1T38 (Lerociclib) is a novel, potent, selective, and orally bioavailable CDK4/6 inhibitor with IC50 values of 0.001 μM, 0.002 μM and 0.028 μM for CDK4, CDK6 and CDK9 respectively.
S8719	AZD4573	AZD4573 is a potent inhibitor of CDK9 (IC50 of <0.004 μM) with fast-off binding kinetics (t_1/2 = 16 min) and high selectivity versus other kinases, including other CDK family kinases.	Cancers (Basel), 2021, 13(15)3906 Front Cell Dev Biol, 2021, 9:641271 Cell Chem Biol, 2020, S2451-9456(20)30380-9
S8722	Samuraciclib (ICEC0942)	Samuraciclib (ICEC0942, CT7001) is a new, orally bioavailable CDK7 inhibitor with an IC50 of 40nM. The IC50 values for CDK1, CDK2, CDK5 and CDK9 were 45-, 15-, 230- and 30-fold higher. ICEC0942 (CT7001) promotes cell cycle arrest and apoptosis.	Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-20-3458
S8727	Atuveciclib (BAY-1143572)	Atuveciclib (BAY-1143572) is potent and highly selective PTEFb/CDK9 inhibitor with IC50 values of 13 nM for CDK9/CycT and the ratio of IC50 values for CDK2/CDK9 is about 100. Outside the CDK family, It inhibits GSK3 kinase with IC50 values of 45 nM and 87 nM for GSK3α and GSK3β respectively.	Nat Commun, 2021, 12(1):7213 Bulletin of the Korean Chemical Society, 2021, 42(3):416-419 Cell Chem Biol, 2020, S2451-9456(20)30380-9
S8730	BAY 1251152	BAY1251152 is a potent PTEFb/CDK9 inhibitor with an IC50 value of 3 nM for CDK9 and an at least 50-fold selectivity against other CDKs in enzymatic assays. BAY1251152 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of gene transcription of various anti-apoptotic proteins.	Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-20-3458
S8783	JSH-150	JSH-150 is a highly selective and potent inhibitor of CDK9 with IC50 of 1 nM.
S8809	MC180295	MC180295 ((rel)-MC180295) is a novel potent and selective CDK9 inhibitor with an IC50 of 5 nM and is at least 22-fold more selective for CDK9 over other CDKs.
S8815	BSJ-03-123	BSJ-03-123 is a phthalimide-based degrader of cyclin-dependent kinase 6 (CDK6). (PROTAC)
S8840	SEL120 (SEL120-34A) hydrochloride	SEL120 (SEL120-34, SEL120-34A) is a novel inhibitor of Cyclin-dependent kinase 8 (CDK8) with IC50 values of 4.4 nM and 10.4 nM for CDK8/Cyclin C and CDK19/CyclinC respectively.
S8863	YKL-5-124	YKL-5-124 is a potent, selective and covalent CDK7 inhibitor with an IC50 of 9.7 nM, 1300 nM and 3020 nM for inhibiting CDK7/Mat1/CycH, CDK2 and CDK9 respectively. It displays biochemical and cellular selectivity for CDK7 over CDK12/13.	Cell, 2021, 184(25):6119-6137.e26 Cell Rep, 2021, 35(4):109013
S8894	SR-4835	SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13 with IC50 of 99 nM and Kd of 98 nM for CDK12 and IC50 of 4.9 nM for CDK13. SR-4835 disables triple-negative breast cancer (TNBC) cells. SR-4835 promotes synergy with DNA-damaging chemotherapy and PARP inhibitors.
S8903	AS2863619	AS2863619 is a small-molecule cyclin-dependent kinase CDK8/19 inhibitor with IC50 of 0.6099 nM and 4.277 nM, respectively. AS2863619 is a potent Foxp3 inducer in T_conv cells.
S8979	THAL-SNS-032	THAL-SNS-032 is a selective Cyclin-dependent kinase 9 (CDK9) degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN).
S8981	NVP-2	NVP-2, a potent, selective, non-neurotoxic and ATP-competitive cyclin dependent kinase 9 (CDK9) inhibitor with IC50 of 0.514 nM for CDK9/CycT activity and induces cell apoptosis.
S9605	Apcin	Apcin (APC inhibitor) is an inhibitor of the E3 ligase activity of the mitotic anaphase-promoting complex/cyclosome (APC/C) that binds to Cdc20 and competitively inhibits the ubiquitylation of D-box-containing substrates.	Prostate, 2021, 10.1002/pros.24257 Breast Cancer, 2021, 10.1007/s12282-021-01242-z
S9650^New	LY3143921 hydrate	LY3143921 hydrate is an orally administered ATP-competitive CDC7 inhibitor.
S9665	Motixafortide (BL-8040)	Motixafortide (BL-8040, BKT140, TF 14016, 4-fluorobenzoyl, 4F-benzoyl-TN14003, T140) is an antagonist of CXCR4 with IC50 of ～1 nM. BL-8040 induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
S9742^New	Indisulam	Indisulam (E7070), a sulfonamide anticancer agent, is a potent carbonic anhydrase (CA) inhibitor that inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Indisulam suppresses the expression of cyclin E and phosphorylation of CDK2, both of which are essential for the G1 to S transition.
S9859^New	BSJ-4-116	BSJ-4-116 is a specific degrader of cyclin-dependent kinase 12 (CDK12). BSJ-4-116 exhibits potent antiproliferative effects.
S9880^New	MS140	MS140 is a specific and highly potent CDK4/6 kinase inhibitor and also a CDK4/6 degrader (PROTAC).
S9901^New	KB-0742 Dihydrochloride	KB-0742 Dihydrochloride is a potent, selective, and orally bioavailable small molecule inhibitor of the transcription elongation cofactor CDK9 with IC50 of 6 nM for CDK9/cyclin T1 inhibition at 10 μM ATP.
A5016	Cyclin B1 Rabbit Recombinant mAb	Cyclin B1 Rabbit Recombinant mAb detects endogenous levels of total Cyclin B1.	Arch Biochem Biophys, 2021, 700:108774 Gastric Cancer, 2019, 10.1007/s10120-019-00977-1 Gastric Cancer, 2019, 10.1007/s10120-019-00977-1
A5053	p27 KIP1 Rabbit Recombinant mAb	p27 KIP1 Rabbit Recombinant mAb detects endogenous levels of total p27 KIP 1.	Aging (Albany NY), 2020, 12(16):16390-16409
A5081	Cdk8 Rabbit Recombinant mAb	Cdk8 Rabbit Recombinant mAb detects endogenous levels of CDK8.
A5127	Cyclin B2 Rabbit Recombinant mAb	Cyclin B2 Rabbit Recombinant mAb detects endogenous level of total Cyclin B2.
A5128	Cdk9 Rabbit Recombinant mAb	Cdk9 Rabbit Recombinant mAb detects endogenous level of total Cdk9.
A5129	Cdk6 Rabbit Recombinant mAb	Cdk6 Rabbit Recombinant mAb detects endogenous level of total Cdk6.
A5197	Cdc16/APC6 Rabbit Recombinant mAb	Cdc16/APC6 Rabbit Recombinant mAb detects endogenous level of total Cdc16/APC6.
A5198	CDC34 Rabbit Recombinant mAb	CDC34 Rabbit Recombinant mAb detects endogenous level of total CDC34.
A5200	Cdc37 Rabbit Recombinant mAb	Cdc37 Rabbit Recombinant mAb detects endogenous level of total Cdc37.
A5268	p57 Kip2 Rabbit Recombinant mAb	p57 Kip2 Rabbit Recombinant mAb detects endogenous level of total p57 Kip2.
S7981	CCT251545	CCT251545 is a potent, orally bioavailable inhibitor of WNT signaling with IC50 of 5 nM in 7dF3 cells. CCT251545 also act as a selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.	Front Cell Dev Biol, 2020, 8:408
E0072^New	Indirubin-3′-oxime	Indirubin-3′-oxime (IDR3O, I3O) is an indirubin analogue that shows favorable inhibitory activity targeting GSK-3β and CDKs. Indirubin-3′-oxime also inhibits JNKs with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM for JNK1, JNK2, and JNK3, respectively. Indirubin-3′-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity.
S4454^New	FIT-039	FIT-039 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), suppressing replication of a broad spectrum of DNA viruses through inhibition of mRNA transcription.
S4482^New	Palbociclib	Palbociclib (Ibrance, PD 0332991) is a highly specific inhibitor of cyclin-dependent kinase 4 (Cdk4) and Cdk6 with IC50 of 11 nM and 16 nM, respectively.	Mol Cancer Ther, 2022, 21(1):48-57 Cell, 2021, 184(25):6119-6137.e26 Genome Biol, 2021, 22(1):176
S5187^New	Ribociclib hydrochloride	Ribociclib (LEE011) hydrochloride is a highly specific dual inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM, respectively.	Biochim Biophys Acta Mol Cell Res, 2021, 1868(7):119044 Mol Cancer Res, 2021, 19(6):1026-1039 Front Oncol, 2021, 11:681530
S5188^New	Ribociclib succinate	Ribociclib (LEE011) succinate (Kisqali) is a highly specific dual inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM, respectively.	Biochim Biophys Acta Mol Cell Res, 2021, 1868(7):119044 Mol Cancer Res, 2021, 19(6):1026-1039 Front Oncol, 2021, 11:681530
S5953^New	Menadione bisulfite sodium	Menadione(Vitamin K3) bisulfite sodium, a fat-soluble compound, is an inhibitor of Cdc25 phosphatase and mitochondrial DNA polymerase γ (pol γ), used as a nutritional supplement.	Life Sci, 2020, 242:117159
S6383^New	1-NM-PP1	1-NM-PP1 (PP1 Analog II, 1NM-PP1, analogue 9) is a potent inhibitor of Src family kinases with IC50 of 4.3 nM and 3.2 nM for v-Src-as1 and c-Fyn-as1, respectively. 1-NM-PP1 also inhibits CDK2-as1, CAMKII-as1 and c-Abl-as2 with IC50 of 5.0 nM, 8.0 nM and 120 nM, respectively.
S6768^New	CC-671	CC-671 is a selectively dual inhibitor of TTK (human protein kinase monopolar spindle 1 [hMps1]) and CDC like kinase 2 (CLK2) with IC50s of 5 nM and 3 nM for TTK and CLK2, respectively.
S6884^New	LY3405105	LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity.
S7371^New	Fadraciclib (CYC065)	Fadraciclib (CYC065) is a novel, orally available ATP-competitive inhibitor of CDK2/CDK9 kinases with IC50 of 5 nM and 26 nM, respectively.
S9650^New	LY3143921 hydrate	LY3143921 hydrate is an orally administered ATP-competitive CDC7 inhibitor.
S9742^New	Indisulam	Indisulam (E7070), a sulfonamide anticancer agent, is a potent carbonic anhydrase (CA) inhibitor that inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Indisulam suppresses the expression of cyclin E and phosphorylation of CDK2, both of which are essential for the G1 to S transition.
S9859^New	BSJ-4-116	BSJ-4-116 is a specific degrader of cyclin-dependent kinase 12 (CDK12). BSJ-4-116 exhibits potent antiproliferative effects.
S9880^New	MS140	MS140 is a specific and highly potent CDK4/6 kinase inhibitor and also a CDK4/6 degrader (PROTAC).
S9901^New	KB-0742 Dihydrochloride	KB-0742 Dihydrochloride is a potent, selective, and orally bioavailable small molecule inhibitor of the transcription elongation cofactor CDK9 with IC50 of 6 nM for CDK9/cyclin T1 inhibition at 10 μM ATP.